Study results of Specific microendoscopic characteristics of intranasal mucosa in patients presenting with chronic rhinosinusitis and treated with sinuforte
Results:
Clinical and instrumental data on treatment with Sinuforte/Nasdoren revealed improvement of general and/or local CRS symptoms, as confirmed by data from contact microendoscopy, in 30 patients (100%).
By day 2 of treatment with Sinuforte/Nasodren, an increase in the quantity of discharge from the nasal cavity of 1.4 times and a decrease in nasal stuffiness of 1.1 times (p<0.001) were observed.
By day 4 of treatment positive changes appeared, both subjective: absence of headache and facial pain in 100% of patients, decrease in nasal stuffiness of 1.8 times (p<0.001) and improve sense of smell; and objective: significant decrease in oedema of the mucosa.
On day 6 after the start of treatment, the intensity of symptoms was significantly reduced in all patients in comparison with parameters on day 4. All subjective improvements were confirmed by objective findings.
At the end of treatment on day 8, 14 (46.7%) patients reported relief from nasal stuffiness, and the remaining patients reported reduced intensity of this symptom; all patients displayed an absence of purulent discharge. Endoscopic examination revealed absence of oedema of the intranasal mucosa in 21 (70%) patients and reduction of oedema in the remaining patients.
Tolerance of the Cyclamen extract was evaluated as “good” in 100% of cases by patients and the researcher using a point scale. Tolerance at the end of the course of treatment was evaluated as “good” in 90% of cases and “excellent” in 10% of cases. There were no unsatisfactory evaluations.
The efficacy of Sinuforte/Nasodren was evaluated cumulatively after phased treatment, taking into account the dynamics of subjective and clinical parameters at each visit as “good” by day 4 and as “excellent” by day 8.
Key messages from this study
- Sinuforte/Nasodren is safe and efficacious for the treatment of patients with CRS
- Sinuforte/Nasodren improves drastically the most frequent symptoms of CRS (facial pain and nasal congestion)
- Sinuforte/Nasodren alleviate rhinosinusitis symptoms from the first application
- Subjective improvements correlate with objective findings
- Sinuforte/Nasodren physiologically resolves CRS exacerbation without disrupting the anatomical integrity of the nasal mucosa
- Tolerance of Sinuforte/Nasodren is rated as excellent or good for both patients and researchers
M. A. KHOROL´SKAYA, S. G. VAKHRUSHEV, N. V. TERSKOVA
Vestn Otorinolaringol 2011; 5: 59
